Source comparison
Tesamorelin vs Retatrutide and GLP-1 Agonists
Tesamorelin and GLP-1 agonists reduce body fat through entirely different pathways. Comparing them directly is like comparing a scalpel to a sledgehammer: both remove material, but the precision and mechanism are unrelated. Increases GH, targets visceral fat S
This comparison does not assign a generated winner or score.
- Tesamorelin and GLP-1 agonists reduce body fat through entirely different pathways. Comparing them directly is like comparing a scalpel to a sledgehammer: both remove material, but the precision and mechanism are unrelated.
- Increases GH, targets visceral fat
- Suppresses appetite, slows gastric emptying
- Fat type targeted
- Visceral (preferentially)
- Total body fat (non-selective)
- Weight loss
- Modest (~0.5-1 kg over 26 weeks)
- Significant (10-15%+ body weight)
- Lean mass effect
- Preserves or increases
- May reduce lean mass
- Appetite effect
- Minimal
- Strong suppression
- Daily burden
- Daily injection
- Weekly injection (semaglutide)
- Tesamorelin does not cause significant total weight loss. It reduces visceral fat specifically while preserving lean mass. GLP-1 agonists produce large-scale weight loss that includes both fat and some lean tissue.
- For individuals whose primary concern is visceral fat around the organs (the metabolically active fat linked to cardiovascular disease and insulin resistance) rather than total body weight, tesamorelin addresses the specific problem. For those who need substantial overall weight reduction, GLP-1 agonists or triple agonists like retatrutide are more appropriate. Some practitioners combine both approaches. For peptide combination strategies, see the peptide stacking guide.